Management of atopic dermatitis using photo(chemo)therapy

  title={Management of atopic dermatitis using photo(chemo)therapy},
  author={Thilo Gambichler},
  journal={Archives of Dermatological Research},
  • T. Gambichler
  • Published 14 January 2009
  • Medicine
  • Archives of Dermatological Research
The conclusions that may be drawn by interpreting the current literature on the efficacy of photo(chemo)therapy in the treatment of atopic dermatitis (AD) are limited by several factors including publication bias, small sample sizes, high variability of parameters used in different studies, and in particular the lack of randomized controlled trials comparing different photo(chemo)therapeutic modalities. The newer ultraviolet (UV) modalities, such as medium-dose UVA1 and narrowband (NB) UVB… 
Management of atopic dermatitis: safety and efficacy of phototherapy
Phototherapy is generally considered to be safe and well tolerated, with a low but established percentage of short-term and long-term adverse effects, with the most common being photodamage, xerosis, erythema, actinic keratosis, sunburn, and tenderness.
Topical tacrolimus vs medium-dose ultraviolet A1 phototherapy in the treatment of atopic dermatitis - a preliminary study in relation to parameters of the epidermal barrier function and high-frequency ultrasonography.
The beneficial influence of both therapies on the course of moderate-severe AD was confirmed, with tacrolimus induced a greater reduction in TEWL, while phototherapy caused the reduction of subepidermal low echogenic band-SLEB within sites affected with pathological lesions.
Long-Term Narrowband UV-B Efficacy in Moderate to Severe Atopic Dermatitis
Narrowband UV-B phototherapy shows high and long-lasting efficacy in AD and response duration seems to be shorter for patients younger than 18 years, while patients with facial involvement and patients with high immunoglobulin E levels respond less to treatment.
Atopic Dermatitis: An Evidence-Based Treatment Update
  • J. Silverberg
  • Medicine
    American Journal of Clinical Dermatology
  • 2014
Investigator-initiated RCTs support the use of the systemic agents cyclosporine, methotrexate, azathioprine and mycophenolate mofetil, and in one RCT, petrolatum was found to be as effective as creams containing ceramides or glycyrrhetinic acid.
Guidelines for treatment of atopic eczema (atopic dermatitis) Part II
The existing evidence for treatment of atopic eczema (atopic dermatitis, AE) is evaluated using the national standard Appraisal of Guidelines Research and Evaluation. The consensus process consisted
Ultraviolet A1 Phototherapy for Fibrosing Conditions
E efficacy and safety aspects of ultraviolet A1 (UV-A1) phototherapy in fibrosing conditions are described and the optimal dosage regimen medium-dose UV-A 1 seems to be linked to the best benefit/risk ratio.
Long-wavelength ultraviolet A (UVA-1) phototherapy for the treatment of patients with atopic dermatitis
The data obtained indicate the effectiveness and safety of the UFA-1-radiation in the treatment of patients with moderate-to-severe atopic dermatitis.
Extracorporeal photochemotherapy as systemic monotherapy of severe, refractory atopic dermatitis: results from a prospective trial.
A small but significant therapeutic effect of ECP was detected in patients with severe, refractory atopic dermatitis, and improvement in quality of life measured by SKINDEX, SF-36, and FACT did not reach statistical significance.


UVA/UVB phototherapy for atopic dermatitis revisited
Both UVA /UVB monotherapy and UVA/UVB + topical CS lead to significant clinical improvement in patients with AD, but the addition of CS reduces the total UVB dose and duration of treatment without influencing the duration of remissions and frequency of side effects.
High-dose UVA1 therapy for atopic dermatitis: results of a multicenter trial.
Narrowband ultraviolet B and medium-dose ultraviolet A1 are equally effective in the treatment of moderate to severe atopic dermatitis.
Combined UVA-UVB versus UVB phototherapy for atopic dermatitis: a paired-comparison study.
Extracorporeal Photopheresis as a Treatment for Patients with Severe, Refractory Atopic Dermatitis
ExP can have a significant therapeutic effect on the skin and quality of life improvement in a selected group of patients with severe AD who are refractory to conventional forms of therapy, however, larger studies are needed to further evaluate its therapeutic potential.
Narrow-band UVB treatment in atopic dermatitis.
Narrow-band UVB (NB-UVB) and combined UVAB treat ten adult patients with symmetrical AD were ment results in half-side comparison study in 10 patients with atopic included in the half- side (right/left) comparison study.
[Comparison of balneophototherapy and UVA/B mono-phototherapy in patients with subacute atopic dermatitis].
Balneophototherapy expands the therapeutic options for patients with subacute atopic dermatitis by showing a statistically significant reduction of the SCORAD score and the cumulative UVB dose was significantly lower in the balneophOTotherapy group.
Narrowband UVB phototherapy in skin conditions beyond psoriasis.
Treatment of Persistent Severe Atopic Dermatitis in 113 Japanese Patients with Oral Psoralen Photo‐Chemotherapy
Photochemotherapy with oral 8‐MOP can be indicated in patients with severe, widespread AD, especially if standard therapy fails, this is the first report of oral PUVA therapy in a large series of Japanese patients with AD.